Last reviewed 2026-05-14 · How we verify

Recombinant Human Follitropin Alfa

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Injection site pain
• Procedural pain
• Headache
• Pelvic pain
• Pelvic discomfort
• Nausea
• Antepartum haemorrhage
• Abortion spontaneous
• Ovarian hyperstimulation syndrome
• Fatigue
• Post procedural complication
• Post procedural discomfort

Key clinical trials

• A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
• Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers (PHASE1)
• Ovarian Hyperstimulation and Fibrin Clot Properties. (NA)
• Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol
• Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?
• Trigger Protocol on the Rate of Pregnancy After Intracytoplasmic Sperm Injection
• Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
• Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Recombinant Human Follitropin Alfa CI brief — competitive landscape report
• Recombinant Human Follitropin Alfa updates RSS · CI watch RSS
• Ferring Pharmaceuticals portfolio CI